A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus–induced prostate-specific antigen responses

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|17|2942-2950

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.17, 2015-09, pp. : 2942-2950

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prostate-specific antigen

By Ornstein D.K.   Pruthi R.S.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 7, 2000-12 ,pp. : 1399-1411

Informa Healthcare

Access to resources Recommend Favorite

Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy

By  

Current Topics in Medicinal Chemistry, Vol. 17, Iss. 16, 2017-04 ,pp. : 1843-1857

Bentham Science Publishers

Access to resources Recommend Favorite

Sipuleucel-T [Provenge] prolongs prostate-specific antigen (PSA) doubling time in patients with androgen-dependent prostate cancer

By  

Inpharma, Vol. 1, Iss. 1564, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

The addition of tesmilifene to mitoxantrone and prednisone reduces pain and prostate-specific antigen levels in patients with painful, hormone-refractory prostate cancer

By  

Inpharma, Vol. 1, Iss. 1518, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Prostate Cancer Screening and Determining the Appropriate Prostate-Specific Antigen Cutoff Values

By Catalona William J.   Loeb Stacy  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 8, Iss. 2, 2010-02 ,pp. : 265-270

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite